Chimerix Inc (CMRX) Receives Consensus Rating of “Hold” from Brokerages

Chimerix Inc (NASDAQ:CMRX) has earned a consensus recommendation of “Hold” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $8.00.

Several analysts have issued reports on CMRX shares. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Chimerix in a research note on Monday, March 19th. BidaskClub raised shares of Chimerix from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 15th. Zacks Investment Research raised shares of Chimerix from a “sell” rating to a “hold” rating in a research note on Tuesday, March 6th. Cowen reissued a “hold” rating and set a $6.00 target price on shares of Chimerix in a research note on Thursday, March 1st. Finally, ValuEngine raised shares of Chimerix from a “sell” rating to a “hold” rating in a research note on Friday, June 1st.

Chimerix stock opened at $4.62 on Tuesday. Chimerix has a 1-year low of $4.17 and a 1-year high of $5.94. The firm has a market capitalization of $219.19 million, a price-to-earnings ratio of -3.06 and a beta of 1.24.

Chimerix (NASDAQ:CMRX) last announced its earnings results on Monday, May 7th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.01. Chimerix had a negative net margin of 1,736.95% and a negative return on equity of 31.97%. The company had revenue of $0.79 million for the quarter, compared to the consensus estimate of $1.12 million. equities research analysts anticipate that Chimerix will post -1.77 EPS for the current fiscal year.

In related news, insider M Michelle Berrey purchased 10,000 shares of the company’s stock in a transaction dated Tuesday, June 12th. The shares were acquired at an average cost of $4.50 per share, with a total value of $45,000.00. Following the completion of the purchase, the insider now owns 325,256 shares of the company’s stock, valued at approximately $1,463,652. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ernest Mario sold 52,553 shares of the company’s stock in a transaction on Monday, May 14th. The stock was sold at an average price of $4.64, for a total transaction of $243,845.92. Following the completion of the transaction, the director now directly owns 12,905 shares in the company, valued at $59,879.20. The disclosure for this sale can be found here. Insiders sold 130,368 shares of company stock worth $616,495 over the last ninety days. 12.50% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of CMRX. Prosight Management LP acquired a new position in shares of Chimerix in the fourth quarter worth $6,846,000. ArrowMark Colorado Holdings LLC boosted its holdings in Chimerix by 58.3% in the fourth quarter. ArrowMark Colorado Holdings LLC now owns 2,707,986 shares of the biopharmaceutical company’s stock worth $12,538,000 after purchasing an additional 996,936 shares in the last quarter. BlackRock Inc. boosted its holdings in Chimerix by 20.7% in the fourth quarter. BlackRock Inc. now owns 3,530,729 shares of the biopharmaceutical company’s stock worth $16,348,000 after purchasing an additional 605,075 shares in the last quarter. Ascend Capital LLC boosted its holdings in Chimerix by 96.9% in the fourth quarter. Ascend Capital LLC now owns 699,664 shares of the biopharmaceutical company’s stock worth $3,240,000 after purchasing an additional 344,311 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Chimerix by 12.6% in the first quarter. Dimensional Fund Advisors LP now owns 2,317,142 shares of the biopharmaceutical company’s stock worth $12,049,000 after purchasing an additional 259,424 shares in the last quarter. 73.49% of the stock is currently owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply